Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-11-23 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics (formerly Vaccibody*)) enters into multi-target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases
Regulatory Filings Classification · 100% confidence The document is titled "Company Announcement" and details a significant business event: a multi-target license and collaboration agreement between Nykode Therapeutics and Regeneron. It outlines financial terms (upfront payment, equity investment, potential milestones, royalties) and strategic rationale. This type of announcement, detailing a major corporate transaction or partnership, is typically classified as a general regulatory announcement or a specific corporate action filing. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal announcement of a significant business development, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a material event disclosure. It is not a 'Capital/Financing Update' (CAP) because the primary focus is the collaboration/licensing deal, not just raising capital, although it includes an equity investment component. It is not a 'Transaction in Own Shares' (POS) as the core is the collaboration, not a buyback. Therefore, RNS is the most appropriate general disclosure category for this material business event announcement.
2021-11-23 English
Nykode Therapeutics (formerly Vaccibody*)) enters into multi-target license and collaboration agreement with Regeneron to develop innovative vaccines against cancer and infectious diseases
Capital/Financing Update Classification · 95% confidence The document announces a significant business event: a multi-target license and collaboration agreement between Nykode Therapeutics and Regeneron, detailing financial terms (upfront payment, equity investment, potential milestones, royalties) and operational responsibilities. This type of announcement, detailing a major strategic partnership or financing activity, aligns best with the 'Capital/Financing Update' (CAP) category, as it involves substantial financial consideration and structuring of future development costs. While it is a press release, its core subject matter is the financial and strategic impact of the deal, rather than just a general regulatory update (RNS) or a report publication announcement (RPA). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the focus on the financial structure of the collaboration, CAP is the most appropriate fit.
2021-11-23 English
Vaccibody AS – Notice of Extraordinary General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled "INNKALLING TIL EKSTRAORDINÆR GENERALFORSAMLING I VACCIBODY AS" (Notice of Extraordinary General Meeting in Vaccibody AS). It details the agenda items for this meeting, including name change proposals, extension of warrant expiry dates, and election of committee members. The text also includes instructions for shareholder registration and proxy submission. This content directly corresponds to the purpose of a notice for a shareholder meeting, which falls under the category of AGM Information (AGM-R), even though it is an *Extraordinary* General Meeting, as AGM-R covers presentations and materials shared during the Annual General Meeting (AGM), and this is the primary document calling for the meeting and outlining its business.
2021-11-23 Norwegian
Vaccibody AS – Notice of Extraordinary General Meeting
AGM Information Classification · 99% confidence The document is explicitly titled "INNKALLING TIL EKSTRAORDINÆR GENERALFORSAMLING I VACCIBODY AS" (Notice of Extraordinary General Meeting in Vaccibody AS). It details the agenda items, including changing the company name and extending the expiry date for warrants, which are typical items requiring shareholder approval at a general meeting. The document serves to call shareholders to the meeting and outline what will be voted upon. This directly corresponds to the definition of materials shared during a General Meeting, which is classified as AGM-R (AGM Information). Although it is an 'Extraordinary' meeting, the classification AGM-R covers general meetings.
2021-11-23 Norwegian
Vaccibody AS – Notice of Extraordinary General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled "Vaccibody AS – Notice of Extraordinary General Meeting" and details the date, time, location, and agenda items for an EGM (Extraordinary General Meeting). The agenda includes a name change, warrant extension, and committee election. This directly relates to shareholder meetings and corporate governance decisions requiring shareholder approval. The closest matching category is AGM-R (AGM Information), as EGM materials often fall under the broader category of General Meeting materials, especially when specific EGM codes are not provided. Although it is a notice, the content is the core material for the meeting itself, not just an announcement that materials are available (which would suggest RPA or RNS). Since it is a notice calling for a meeting with the agenda, AGM-R is the most appropriate fit among the provided options.
2021-11-23 English
Vaccibody AS – Notice of Extraordinary General Meeting
AGM Information Classification · 95% confidence The document is explicitly titled 'Vaccibody AS – Notice of Extraordinary General Meeting' and calls for an EGM on November 30, 2021, detailing the agenda items (name change, warrant extension, committee election). This directly relates to shareholder meetings and voting procedures. While it mentions the 'notice of the EGM is attached,' the core content is the official call and information regarding the meeting itself. This aligns best with the purpose of an AGM/EGM related filing. Since the options include 'AGM-R' (AGM Information) and 'DEF 14A' (Proxy Solicitation), and this is a notice for an EGM, 'AGM-R' is the most appropriate fit for general meeting materials, even though it's an EGM, as there is no specific EGM code, and it precedes the actual voting results (DVA).
2021-11-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.